News
-
-
COMMUNIQUÉ DE PRESSE
Alset AI Announces Strategic $3 Million Unsecured Term Loan Facility to Advance Flagship Cloud Compute Business Towards Positive Operating Income in 2026
Alset AI secures $3M unsecured term loan from insider for Lyken.AI, aiming to fuel revenue growth and enhance balance sheet with a conservative interest rate of 6%, Alset expecting positive operating income by 2026 -
COMMUNIQUÉ DE PRESSE
Huawei Digital Power Helps ASEAN Achieve Zero-Carbon Transformation with All-Scenario Grid Forming Technologies
Huawei Digital Power showcases grid forming technologies at AEBF-25 in Malaysia, supporting ASEAN's zero-carbon transformation with high-quality Smart PV+ESS solutions and innovations -
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire
Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire. Recommandation basée sur l'étude LUNA 3 montrant des améliorations significatives pour les patients -
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
CHMP recommends Sanofi's Wayrilz for EU approval to treat immune thrombocytopenia, targeting disease root cause through multi-immune modulation. Positive phase 3 study results showcased rapid platelet response and symptom improvements -
COMMUNIQUÉ DE PRESSE
Eleving Group increases 2025/2030 bond issue offering amount to up to EUR 300 million due to strong investor demand
Eleving Group increases 2025/2030 bond issue amount to EUR 300 million due to high investor demand. Public offer in multiple countries with 9.5%-9.75% annual interest rate -
-
-
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Sanofi fournit une mise à jour de l’examen réglementaire du Rezurock dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
Sanofi demande un réexamen après un avis négatif du CHMP pour le Rezurock dans le traitement de la maladie chronique du greffon contre l’hôte en Europe -
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Sanofi announces negative CHMP opinion on Rezurock for chronic graft-vs-host disease in the EU but plans to seek re-examination. Rezurock has shown efficacy in clinical studies
